Following this introduction, Chapter II summarizes the principal findings of the study. Chapter III provides a detailed discussion of the distinctions between the concepts of "access" and "utilization" that underlie the entire report. Chapters IV and V detail the findings of the primary research interviews investigating the state of access to and utilization of newer antidepressant and antipsychotic medications during the term of this study (1998-1999). Chapter VI presents an analysis of Medicaid pharmaceutical claims designed to establish patterns of antidepressant and antipsychotic utilization by state Medicaid programs between 1995 and 1998. In addition this chapter compares utilization of these psychotherapeutics with the utilization of other classes of medications to gain insight into whether the uptake of newer psychotherapeutics by Medicaid is slower than for other classes. Chapter VII reviews the pharmacoeconomic literature for antidepressant and antipsychotic medications. Finally Chapter VIII highlights areas for further research and identifies key trends and potential issues that may raise policy concerns in the future.